pharmaceutical raw materials Galantamine Hydrobromide 1953-04-4 API Manufacturer made in China
1. Product Name: galantaminehydrobromide
2. Other names: galanthaminehci;
galanthaminehbr; galanthaminehydromide; galanthaminehdromide;
3. CAS No.: 1953-04-4
4. Molecular formula: c17h22brno3
5. Molecular weight: 368.27
6. EINECS No.: 217-780-5
7. Melting point: 256 ° C
8. Specific rotation: d20-93.1 ° (C = 0.1015in 15mlh2o)
9. Refractive index: - 95 ° (C = 1.4, H2O)
10. Storage conditions: − 20 ° C
11. Solubility: sparingly soluble in waer, very slightly soluble in
anhydrousethanol.it resolvesindulutesolutions of alkalihydroxides
12. Appearance: white crystalline powder, odorless, bitter, soluble
in water, slightly soluble in ethanol, insoluble in acetone,
chloroform, ether and benzene.
Galantamine hydrobromide is a tertiary amino alkaloid and is a
reversible competitive inhibitor of cholinesterase. With the
deepening understanding of the pathogenesis of alzheimer's disease
(AD), the study on the treatment of AD started in the early 1980s.
In 1987, American scholar Bonnie et al. were the first to obtain
the patent for the treatment of AD with galantamine hydrobromide.
Since then, pharmacology, pharmacodynamics and pharmacokinetics
experiments related to this have been carried out in various
countries. The results showed that galantamine hydrobromide, as a
second generation cholinesterase inhibitor, blocked the degradation
of acetylcholine by this enzyme through competing with
acetylcholine to bind with cholinesterase in the synapses, thus
increasing the concentration of acetylcholine in the brain.
It is suitable for benign memory disorder to improve patients'
ability of pointing memory, associative learning, image recall,
meaningless figure recognition and portrait recall. It also
improves the memory impairment caused by dementia patients and
brain temperament disease.
USES: 1. Used for motor disorders, multiple neuritis and spinal
radiculitis caused by neurological diseases and trauma. 2.
Cholinesterase inhibitor reverses scopolamine induced memory loss.